CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 52 enrolled
Drug / intervention
Cardiva Medical VASCADE VCSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02948257
NCT02948257N/ACompleted

Multi-center, Prospective, PM Registry for Procedural Outcomes Using the Cardiva VASCADE VCS for Closing the Femoral Arteriotomy After Percutaneous Endovascular Procedures Via Antegrade Access.

Cardiva Medical, Inc.·observational·Posted Oct 28, 2016·Updated Jan 18, 2020

In Brief

An observational study evaluating Cardiva Medical VASCADE VCS for Surgical Wound. Completed, enrolled 52 participants across 5 sites.

Detailed Summary

The objective of the registry is to collect procedural outcomes data when the Cardiva VASCADE Vascular Closure System (VCS) is used to seal femoral arterial access sites at the completion of ipsilateral peripheral interventional procedures performed through 5-7F introducer sheaths via an antegrade approach.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSurgical Wound
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 28, 2016
Enrollment StartJan 19, 2017
Primary CompletionSep 18, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.7 years ago

Interventions

Cardiva Medical VASCADE VCSdevice

At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.